CN108148072A - A kind of spectinomycin derivative and its preparation method and application - Google Patents
A kind of spectinomycin derivative and its preparation method and application Download PDFInfo
- Publication number
- CN108148072A CN108148072A CN201810139685.6A CN201810139685A CN108148072A CN 108148072 A CN108148072 A CN 108148072A CN 201810139685 A CN201810139685 A CN 201810139685A CN 108148072 A CN108148072 A CN 108148072A
- Authority
- CN
- China
- Prior art keywords
- spectinomycin
- acid
- derivative
- amido protecting
- spectinomycin derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of spectinomycin derivatives and its preparation method and application.For spectinomycin molecule in the deficiencies in the prior art such as anti-mycobacterium tuberculosis effect is poor; to improve the targeting to tuberculosis cell, the dissolubility for enhancing drug, alleviating toxicity of the drug to normal cell; the present invention is by regarding the natural amino acid with good biocompatibility and compatibility as carrier; it is introduced into spectinomycin molecule by the preparation method of the amido protecting of spectinomycin, carbonyl reduction, amidation, deprotection, forms a kind of novel spectinomycin derivative.It is demonstrated experimentally that the spectinomycin derivative is improved the antibacterial activity of tubercle bacillus, and treating tuberculosis action time is extended.Since such spectinomycin derivative has preferably tubercle bacillus resistant activity, there is preferable application prospect in antituberculotic.
Description
Technical field
The invention belongs to field of medicaments, are related to a kind of spectinomycin derivative and its preparation method and application, more particularly to
One kind is using spectinomycin as parent, the spectinomycin derivative of the new substituent group of carbonyl on A rings.
Background technology
Spectinomycin (spectinomycin) is also known as spextinomyxin or grand rhzomorph (actinospectacin), is one
Kind alkali water-soluble antibiotic.It is initially reported and it is attributed to aminocyclitol antibiotic (aminocyclitol), the eighties
After be reclassified as aminoglycoside antibiotics (aminoglycoside).This is family by based on aminocyclitol and amino sugar
The antibiotic that class is combined into glycosidic bond.So some scholars particularly point out such antibiotic strict difinition should be aminocyclitol-
Aminoglycoside antibiotics.Chinese Pharmacopoeia version in 2000, British Pharmacopoeia 2000 editions and United States Pharmacopeia 24 editions have included the drug.
Mason of nineteen sixty, U.S. Abbott laboratories and Upjohn companies et al. extracts grand sight from grand sight streptomycete for the first time
Mycin.Spectinomycin intramuscular injection absorbs fast, it is difficult to which intestinal absorption is made generally in sterile suspension injection.Clinical practice uses grand sight
The form of salt.It is initially sulfate, molecular formula C14H24N2O7·H2SO4·4H2O, the seventies are developed more suitable for suspending
The hydrochloride of the solubility bigger of injection.Spectinomycin hydrochloride be rice white crystal, molecular formula C14H24N2O7·2HCl·5H2O,
Molecular weight 495.35.Spectinomycin is a kind of broad-spectrum antibiotic, has antibacterial action to Gram-negative and gram-positive bacteria.
Clinically it is exclusively used in infecting caused by treatment Neisseria gonorrheae (Neisseria gonorrhoeae), for tubercle bacillus
With certain antibacterial action, but it is poor to its antibacterial effect.
Amino acid is to form organism protein and the most basic substance related with vital movement.Amino acid derivativges are wide
It is general to be used as Antibiotics drug.Inflammatory cell is bigger than normal cell to the demand of certain amino acid, especially tuberculosis infection
Cell.By special amino acid diet or infusion formula, can reach improves body nutrition condition, enhances immunity of organism work(
Can, inhibit tuberculosis cell growth, improve the resistivity to disease.Amino acid is introduced into drug as the endogenous substance of life
Molecule can promote absorption of the cell to drug, while reduce the toxicity of drug, and the antituberculotic to seek efficient, less toxic is opened
Ward off approach.With the continuous research to its structure-activity relationship and mechanism of action, amino acids antituberculotic is in antituberculotic
Have broad application prospects.
Invention content
For spectinomycin molecule in the deficiencies in the prior art such as anti-mycobacterium tuberculosis effect is poor, the present invention will be by that will have
Good biocompatibility and the natural amino acid of compatibility are introduced into spectinomycin molecule, raising pair as carrier
The targeting of tuberculosis cell, the dissolubility for enhancing drug alleviate toxicity of the drug to normal cell.
First of the present invention is designed to provide a kind of spectinomycin derivative, which is by following technical solution
It realizes：The analog derivative, structural formula such as formula (I) are mould by the way that 20 kinds of natural amino acids (AA-OH) are introduced between grand sight
On the A cyclocarbonyls of plain molecule.
The spectinomycin derivative, general structure such as formula (I)：
The spectinomycin molecular structural formula such as formula (II)：
20 kinds of natural amino acid structure formulas are as follows, general structure AA-OH：
Above-mentioned one kind A cyclocarbonyls connect the spectinomycin derivative of new substituent group, and concrete structure formula is as follows：
Second object of the present invention is to provide a kind of preparation method of spectinomycin derivative, which is by such as
What lower technical solution was realized：
A kind of preparation method of spectinomycin derivative, includes the following steps：
(1) amido protecting of spectinomycin；
(2) carbonyl reduction of step (1) amido protecting product；
(3) amidation：In organic solvent, the natural amino acid of step (2) carbonyl reduction product and amido protecting is added in,
The molar ratio of the natural amino acid of step (2) product and amido protecting is 1:1~2, under the catalysis of condensing agent, reaction 1
~48 hours, obtain product, compound 24~43；
(4) amidated products are deprotected to obtain spectinomycin derivative.
Further, the step (1), under the conditions of 10~20 DEG C, spectinomycin hydrochloride is dissolved in the water, reaction
System pH is 2~4, adds in alkali, and CbzCl is added in organic solution and is stirred evenly, reaction system is then added in, at 25~50 DEG C
Under the conditions of react 1~48h, the molar ratio of the spectinomycin hydrochloride compound and CbzCl are 1:1~3, pass through acid for adjusting pH
To 6.5~7.5, amido protecting product Compound 22 is obtained through processing step.
The step (2) in organic solvent, adds in amido protecting product and ammonium nitrate described in step (1), the ammonia
It is 1 that base, which protects the molar ratio of product and ammonium nitrate,:10~15, under acid catalysis, reaction is stirred at room temperature to clarifying, by borane reagent point
It criticizes and adds in reaction system, the molar ratio of the amido protecting product and borane reagent is 1:At 0.5~1.5,20~40 DEG C, stirring
1~2h is reacted, carbonyl reduction product Compound 21 is obtained through processing step.
The step (4) in acidic aqueous, adds in step (3) described amidated products, the water at 10~50 DEG C
Solution 1~48h of reaction, obtains through processing step, obtains spectinomycin derivative.
Further, the condensing agent be o- (7- nitrogen benzotriazole)-N, N, N, N- tetramethylurea hexafluorophosphoric acid esters
(HATU), it is any one in benzotriazole -1- tetramethyls hexafluorophosphoric acid ester (HBTU), N-N '-diisopropylcarbodiimide (DIC)
Kind.
Further, the alkali is sodium bicarbonate, saleratus, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, pyrrole
Any one in pyridine, diethylamine, triethylamine or n,N-Dimethylaniline.
Further, the acid is organic acid or inorganic acid；The organic acid is formic acid, acetic acid, oxalic acid, tartaric acid, breast
Any one in acid, citric acid or benzoic acid；The inorganic acid is any one in hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid.
Further, 1~6mol/L of concentration range of the acid.
Further, the borane reagent is sodium borohydride, lithium borohydride, zinc borohydride, 9- boron-bicyclic [3.3.1] nonane
Any one or more in dimer, borane-pyridine, borane-methyl pyridine, borane-dimethylsulphide or borine-tetrahydrofuran.
Further, the processing step is detached or is used column chromatography method for recrystallization method.
Organic solvent of the present invention includes but not limited to methanol, ethyl alcohol, propyl alcohol, butanol, isopropanol, the tert-butyl alcohol, two
Chloromethanes, chloroform, 1,2- dichloroethanes, carbon tetrachloride, ethyl acetate, ether, tetrahydrofuran, six alkane of Isosorbide-5-Nitrae-dioxy, benzene, first
Benzene, acetone, second cyanogen, dimethyl sulfoxide or n,N-Dimethylformamide.
Third object of the present invention is to provide a kind of application of spectinomycin derivative in antituberculotic.To knot
Pyrenomycetes H37Rv activity investigate and antibiotic after benefit the result shows that：The introducing of natural amino acid so that spectinomycin derivative
The antibacterial activity of tubercle bacillus is improved, and treating tuberculosis action time is extended.
The gain effect of the present invention is as follows：
1st, the present invention provides a kind of novel spectinomycin derivatives.
2nd, spectinomycin derivative synthetic reaction method of the present invention is simple, reaction condition is mild, easy to operate, reagent green
Environmental protection, suitable for industrial production.
3rd, spectinomycin derivative of the present invention is confirmed through pharmacodynamics test：With similar to spectinomycin amide derivatives
Treating tuberculosis acts on, and there is spectinomycin derivative the toxicity lower than spectinomycin amide derivatives and more significant drug effect to make
With.
4th, spectinomycin derivative can be applied to prepare the drug for the treatment of tuberculosis.
Specific embodiment
The technical solution in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example is only part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's all other embodiments obtained without creative efforts belong to the model that the present invention protects
It encloses.
Embodiment 1
The amido protecting of step (1) spectinomycin；
1mol spectinomycin hydrochlorides are added in 400mL water, after system temperature is down to 10 DEG C, reaction system pH for 2~
4, add in sodium bicarbonate stirring and dissolving.1mol CbzCl are added in 250mL acetone after stirring evenly, add in reaction system,
0.5 is reacted at less than 20 DEG C, the reaction was continued after rising to 25 DEG C 0.5h.Use 1mol/L sulfuric acid regulation system pH to 6.5.It will
350mL ethyl acetate adds in system, stratification.Water phase is extracted again with 150mL ethyl acetate, merges organic phase, will be organic molten
Agent is evaporated, and column chromatography purifying is dried 16 hours using oil pump, obtains compound 22, yield 82.65%.
lH-NMR(DMSO-d6)δ7.32(m,10H),5.10(m,4H),4.69(8,2H),4.61(m,1H),4.49(m,
1H),4.37(m,1H),4.16(m,1H),4.00(m,1H),3.36(m,2H),3.07(s,3H),2.97(s,3H),2.80(m,
2H), 2.41 (d, J=14Hz, 2H), 1.36 (d, J=6Hz, 3H)
13C NMR(DMSO-d6)δ156.3(s),136.7(s),128.2(d),127.9(d),127.8(d),127.7
(d),100.7(a),92.2(d),89.2(s),78.9(s),73.5(d),67.9(d),66.9(t),64.2(t),60.0(d),
56.3(d),31.5(q),31.0(q),25.8(9).
Step (2)：The carbonyl reduction of step (1) product
The compound 22 of 1mol and 10mol ammonium nitrate are added in 1L acetate methanol solution, are stirred at room temperature to clarification, it will
0.5mol sodium borohydrides are added in reaction system in three batches, and 1h is stirred at room temperature, and are spin-dried for solvent, make to be extracted with ethyl acetate, dry,
Column chromatography for separation obtains compound 21.
1H NMR(400MHz,Methanol-d4)δ7.46-7.19(m,10H),5.30-4.98(m,4H),4.91(s,
1H), 4.53 (t, J=10.5Hz, 1H), 4.24-3.82 (m, 7H), 3.18-3.01 (m, 6H), 1.92-1.77 (m, 1H),
1.68-1.61 (m, 1H), 1.25 (d, J=5.9Hz, 3H)
MS-ESI:m/z 602(M++H).
Step (3)：Amidation
The alanine of 1mol compounds 21 and 1mol amido protectings is added in dichloromethane, adds in condensing agent 1mol
HBTU is stirred to react 48h at 20 DEG C.Organic solvent extracts, and washes, dry, and column chromatography obtains compound 24.
Step (4)：Deprotection obtains spectinomycin derivative
It by compound 24, adds in HCl/MeOH, 48h is hydrolyzed at 10 DEG C, concentrate, column chromatography, recrystallization obtains grand sight
Adm derivative, compound 1, yield 58%.
lH-NMR(DMSO-d6)δ8.76(s,2H),8.14(s,1H),5.52(m,2H),5.41(s,1H),5.37(s,
1H),4.62(s,1H),4.37(s,1H),3.90(m,1H),3.70(m,1H),3.69(m,1H),3.67(m,1H),3.44(m,
2H),3.39(m,1H),3.26(s,6H),2.77(m,1H),2.57(m,1H),1.80(m,2H),1.25(m,6H).
13C NMR(DMSO-d6)δ171.4,116.0,104.7,88.9,78.5,72.2,65.1,64.1,62.2,59.1,
50.2,49.9,34.6,27.4,21.3,16.8.
Embodiment 2
The amido protecting of step (1) spectinomycin；
1mol spectinomycin hydrochlorides are added in 400mL water, after system temperature is down to 15 DEG C, reaction system pH for 2~
4, add in triethylamine stirring and dissolving.3mol CbzCl are added in 250mL methanol after stirring evenly, reaction system is added in, small
12h is reacted at 20 DEG C, the reaction was continued after rising to 50 DEG C 12h.With hydrochloric acid regulation system pH to 7.350mL ethyl acetate is added in
System, stratification.Water phase is extracted again with 150mL ethyl acetate, merges organic phase, organic solvent is evaporated, column chromatography purifying,
It is dried 16 hours using oil pump, obtains product 22, yield 90.30%.
Step (2)：The carbonyl reduction of step (1) product
The compound 22 of 1mol and 15mol ammonium nitrate are added in 1L alcohol benzoate solutions, are stirred at room temperature to clarification, it will
1mol 9- boron-bicyclic [3.3.1] nonane dimer is added in reaction system in four batches, is stirred to react 2h at 20 DEG C, is spin-dried for molten
Agent makes to be extracted with ethyl acetate, dry, and column chromatography for separation obtains compound 21.
Step (3)：Amidation
The arginine of 1mol compounds 21 and 2mol amido protectings is added in dichloromethane, adds in condensing agent 1mol
HATU is stirred to react 12h at 30 DEG C.Organic solvent extracts, and washes, dry, and column chromatography obtains compound 25.
Step (4)：Deprotection obtains spectinomycin derivative
Compound 25 adds in acetic acid/ethyl alcohol, 1h is hydrolyzed at 50 DEG C, concentrates, column chromatography, and it is mould to obtain grand sight for recrystallization
Plain derivative, compound 2, yield 47%.
lH-NMR(DMSO-d6)δ8.74(s,2H),8.15(s,1H),7.84(s,1H),6.63(s,2H),5.52(m,
2H),5.43(s,1H),5.34(s,1H),4.67(s,1H),4.35(s,1H),3.92(m,1H),3.73(m,1H),3.68(m,
1H), 3.44~3.21 (m, 12H), 2.79 (m, 1H), 2.59 (m, 1H), 2.50 (s, 1H), 1.89~1.51 (m, 6H), 1.24
(m,3H).
13C NMR(DMSO-d6)δ170.7,158.0,116.0,104.6,88.1,78.3,72.5,65.8,64.3,
62.4,60.0,54.3,50.0,41.2,35.2,27.6,25.3,24.2,21.3.
Embodiment 3
The amido protecting of step (1) spectinomycin；
1mol spectinomycin hydrochlorides are added in 400mL water, after system temperature is down to 10 DEG C, reaction system pH for 2~
4, add in n,N-Dimethylaniline stirring and dissolving.2molCbzCl is added in 250mL tetrahydrofurans after stirring evenly, added in anti-
System is answered, reacts 2h at 15 DEG C, the reaction was continued after rising to 35 DEG C 10h.With hydrochloric acid regulation system pH to 7.5.By 350mL acetic acid
Ethyl ester adds in system, stratification.Water phase is extracted again with 150mL ethyl acetate, is merged organic phase, organic solvent is evaporated, column
Chromatographic purifying is dried 16 hours using oil pump, obtains product 22, yield 87.54%.
Step (2)：The carbonyl reduction of step (1) product
The compound 22 of 1mol and 12mol ammonium nitrate are added in 1L lactic acid methanol solutions, are stirred at room temperature to clarification, it will
0.5mol borane-methyl pyridines are added portionwise in reaction system, are stirred to react 1.5h at 40 DEG C, are spin-dried for solvent, use acetic acid second
Ester extracts, dry, and column chromatography for separation obtains compound 21.
Step (3)：Amidation
The asparagine of 1mol compounds 21 and 1.5mol amido protectings is added in DMF, adds in condensing agent 1mol
DIC is stirred to react 1h at 40 DEG C.Organic solvent extracts, and washes, dry, and column chromatography obtains compound 26.
Step (4)：Deprotection obtains spectinomycin derivative
Compound 26 adds in lactic acid/ethyl alcohol, 12h is hydrolyzed at 30 DEG C, concentrates, column chromatography, and recrystallization obtains grand sight
Adm derivative, compound 3, yield 59%.
lH-NMR(DMSO-d6)δ8.78(s,2H),8.13(s,1H),7.03(s,1H),5.51(m,2H),5.47(s,
1H), 5.39 (s, 1H), 4.63 (s, 1H), 4.31 (s, 1H), 3.90~3.87 (m, 2H), 3.70~3.68 (m, 2H), 3.44~
3.39 (m, 3H), 3.28 (s, 6H), 2.77~2.56 (m, 4H), 1.89~1.63 (m, 2H), 1.20 (m, 3H)
13C NMR(DMSO-d6)δ172.3,171.4,116.0,104.9,88.7,78.7,72.4,65.4,64.2,
62.8,59.9,50.4,49.8,39.8,34.8,27.5,22.0.
Embodiment 4
It is similar with 1 step of embodiment, obtain spectinomycin derivative, compound 4~20.The yield of compound 4~20,
Characterize data is as follows：
Compound 4, yield 31%.
lH-NMR(DMSO-d6)δ12.57(s,1H),8.73(s,1H),8.14(s,1H),5.55(m,2H),5.43(s,
1H), 5.35 (s, 1H), 4.67 (s, 1H), 4.30 (s, 1H), 3.90~3.69 (m, 4H), 3.44~3.39 (m, 3H), 3.26
(s, 6H), 2.92~2.54 (m, 4H), 1.90~1.60 (m, 2H), 1.29 (m, 3H)
13C NMR(DMSO-d6)δ174.3,171.0,116.3,104.7,88.9,78.5,72.8,65.3,64.7,
62.2,59.1,50.4,49.8,42.7,34.8,27.4,22.8.
Compound 5, yield 70%.
lH-NMR(DMSO-d6)δ8.77(s,1H),8.18(s,1H),5.54(m,2H),5.44(s,1H),5.33(s,
1H), 4.66 (s, 1H), 4.32 (s, 1H), 3.92~3.67 (m, 4H), 3.47~3.33 (m, 3H), 3.22 (s, 6H), 3.19~
2.94 (m, 2H), 2.77~2.57 (m, 2H), 1.88~1.64 (m, 2H), 1.41 (s, 1H), 1.24 (m, 3H)
13C NMR(DMSO-d6)δ171.3,115.3,104.4,88.8,78.0,72.2,65.5,64.1,62.7,59.9,
57.3,50.7,34.4,30.0,27.7,21.8.
Compound 6, yield 47%.
lH-NMR(DMSO-d6)δ8.76(s,1H),8.14(s,1H),7.03(s,1H),5.52(m,2H),5.47(s,
1H), 5.31 (s, 1H), 4.62 (s, 1H), 4.37 (s, 1H), 3.97~3.69 (m, 3H), 3.49~3.39 (m, 3H), 3.22
(s, 6H), 3.20 (m, 1H), 2.71~2.55 (m, 2H), 2.05~1.64 (m, 6H), 1.27 (m, 3H)
13C NMR(DMSO-d6)δ173.6,170.7,116.0,104.7,88.9,78.5,72.2,65.1,64.1,
62.2,59.1,52.5,49.9,34.6,32.6,30.2,27.4,21.3.
Compound 7, yield 65%.
lH-NMR(DMSO-d6)δ12.01(s,1H),8.77(s,1H),8.11(s,1H),7.03(s,1H),5.57(m,
2H), 5.41 (s, 1H), 5.37 (s, 1H), 4.67 (s, 1H), 4.33 (s, 1H), 3.90~3.39 (m, 6H), 3.27 (s, 6H),
3.21 (m, 1H), 2.77~1.64 (m, 8H), 1.24 (m, 3H)
13C NMR(DMSO-d6)δ173.6,170.7,116.0,104.7,88.9,78.5,72.7,66.2,64.7,
62.7,59.7,52.9,49.6,34.9,30.7,27.7,26.4,21.5.
Compound 8, yield 63%.
lH-NMR(DMSO-d6)δ8.70(s,1H),8.17(s,1H),5.57(m,2H),5.47(s,1H),5.31(s,
1H), 4.62 (s, 1H), 4.37 (s, 1H), 3.90~3.70 (m, 3H), 3.54 (s, 2H), 3.46~3.39 (m, 3H), 3.27
(s, 6H), 2.77~2.57 (m, 2H), 1.90~1.60 (m, 2H), 1.27 (m, 3H)
13C NMR(DMSO-d6)δ170.4,116.8,104.9,88.1,78.0,72.2,66.0,64.1,62.0,59.9,
49.9,43.9,34.4,27.4,21.3.
Compound 9, yield 53%.
lH-NMR(DMSO-d6)δ13.00(s,1H),8.86(s,1H),8.73(s,1H),8.14(s,1H),7.66(s,
1H), 5.58 (m, 2H), 5.40 (s, 1H), 5.37 (s, 1H), 4.61 (s, 1H), 4.39 (s, 1H), 3.95~3.39 (m, 7H),
3.29 (s, 6H), 3.17~2.59 (m, 4H), 1.89~1.61 (m, 2H), 1.20 (m, 3H)
13C NMR(DMSO-d6)δ171.6,136.2,131.3,117.9,116.2,104.3,88.8,78.5,72.7,
65.1,64.7,62.2,59.1,54.1,49.9,34.6,32.2,27.0,21.1.
Compound 10, yield 41%.
lH-NMR(DMSO-d6)δ8.76(s,1H),8.16(s,1H),5.58(s,2H),5.44(s,1H),5.36(s,
1H), 4.67 (s, 1H), 4.34 (s, 1H), 3.98~3.36 (m, 6H), 3.26 (s, 6H), 2.77~2.57 (m, 2H), 1.87~
1.55 (m, 5H), 1.24~0.99 (m, 9H)
13C NMR(DMSO-d6)δ170.7,117.1,104.2,88.1,78.8,72.2,65.5,64.4,62.9,59.7,
57.7,49.2,39.6,34.6,27.4,24.1,21.1,14.8,10.9.
Compound 11, yield 67%.
lH-NMR(DMSO-d6)δ8.74(s,1H),8.12(s,1H),5.52(s,2H),5.46(s,1H),5.32(s,
1H), 4.66 (s, 1H), 4.30 (s, 1H), 3.90~3.34 (m, 5H), 3.26 (s, 6H), 3.21~2.57 (m, 3H), 1.89~
1.64 (m, 3H), 1.34~1.24 (m, 5H), 0.91 (d, 6H)
13C NMR(DMSO-d6)δ170.2,116.1,104.3,88.2,78.6,72.7,65.1,64.1,62.2,59.1,
53.7,49.9,41.4,34.6,27.1,24.4,22.5,21.3.
Compound 12, yield 62%.
lH-NMR(DMSO-d6)δ8.72(s,1H),8.10(s,1H),5.55(s,2H),5.43(s,1H),5.33(s,
1H), 4.69 (s, 1H), 4.37 (s, 1H), 3.92~3.39 (m, 6H), 3.27 (s, 6H), 3.21~2.59 (m, 5H), 1.89~
1.24(m,13H).
13C NMR(DMSO-d6)δ170.7,116.0,104.7,88.9,78.5,72.2,65.7,64.3,62.7,59.3,
54.6,49.7,42.0,34.5,34.2,28.6,27.4,22.3,21.4.
Compound 13, yield 28%.
lH-NMR(DMSO-d6)δ8.71(s,1H),8.14(s,1H),5.53(s,2H),5.44(s,1H),5.39(s,
1H), 4.65 (s, 1H), 4.36 (s, 1H), 3.92~3.38 (m, 6H), 3.25 (s, 6H), 3.21~2.57 (m, 5H), 2.06~
1.64(m,7H),1.20(m,3H).
13C NMR(DMSO-d6)δ170.1,116.7,104.2,88.2,78.1,72.1,65.2,64.9,62.9,59.1,
53.6,49.1,34.6,34.3,29.3,27.4,21.3,15.4.
Compound 14, yield 46%.
lH-NMR (DMSO-d6) δ 8.86 (s, 1H), 8.17 (s, 1H), 7.19~7.14 (m, 5H), 5.57 (s, 2H),
5.41 (s, 1H), 5.35 (s, 1H), 4.62 (s, 1H), 4.39 (s, 1H), 3.95~3.19 (m, 9H), 3.26 (s, 6H), 2.77
~2.57 (m, 2H), 1.89~1.64 (m, 2H), 1.24 (m, 3H)
13C NMR(DMSO-d6)δ171.1,136.6,128.6,125.9,116.0,104.7,88.1,78.5,72.2,
65.1,64.2,62.1,59.2,56.3,49.2,38.6,34.3,27.4,21.3.
Compound 15, yield 71%.
lH-NMR(DMSO-d6)δ8.12(s,1H),5.59(s,2H),5.47(s,1H),5.31(s,1H),4.61(s,
1H), 4.32 (s, 1H), 3.92~3.38 (m, 7H), 3.21 (s, 6H), 2.80~2.57 (m, 4H), 2.00~1.54 (m, 7H),
1.23(m,3H).
13C NMR(DMSO-d6)δ168.3,116.0,104.7,88.9,78.5,72.2,65.1,64.2,63.4,62.2,
59.2,49.3,45.6,34.2,30.9,27.4,24.9,21.2.
Compound 16, yield 67%.
lH-NMR(DMSO-d6)δ8.96(s,1H),8.14(s,1H),5.55(s,2H),5.43(s,1H),5.32(s,
1H), 4.90 (s, 1H), 4.63 (s, 1H), 4.31 (s, 1H), 4.16~3.38 (m, 9H), 3.27 (s, 6H), 2.77~2.59
(m, 2H), 1.89~1.64 (m, 2H), 1.21 (m, 3H)
13C NMR(DMSO-d6)δ171.4,116.2,104.2,88.1,78.3,72.9,65.1,64.1,62.2,61.6,
59.1,54.1,49.8,34.2,27.4,22.3,21.1.
Compound 17, yield 67%.
lH-NMR(DMSO-d6)δ8.98(s,1H),8.17(s,1H),5.57(s,2H),5.41(s,1H),5.32(s,
1H), 4.61 (s, 1H), 4.32 (s, 1H), 3.95~3.36 (m, 6H), 3.21 (s, 6H), 2.71~2.52 (m, 2H), 1.82~
1.62 (m, 2H), 1.24~1.16 (m, 6H)
13C NMR(DMSO-d6)δ200.4,116.2,104.9,88.9,78.7,72.2,70.3,66.7,65.3,64.9,
62.7,59.1,49.6,34.6,27.1,21.5,19.0.
Compound 18, yield 67%.
lH-NMR (DMSO-d6) δ 10.86 (s, 1H), 8.96 (s, 1H), 8.16 (s, 1H), 7.58~7.33 (m, 2H),
7.20 (s, 1H), 7.06~6.98 (m, 2H), 5.52 (s, 2H), 5.40 (s, 1H), 5.37 (s, 1H), 4.62 (s, 1H), 4.31
(s, 1H), 3.95~3.06 (m, 9H), 3.27 (s, 6H), 2.77~2.55 (m, 2H), 1.89~1.62 (m, 2H), 1.24 (m,
3H).
13C NMR(DMSO-d6)δ171.4,136.5,127.4,123.0,121.7,119.8,118.8,116.0,
111.1,107.1,104.7,88.9,78.5,72.2,65.1,64.1,62.2,59.1,57.4,49.9,34.6,27.4,
21.3.
Compound 19, yield 51%.
lH-NMR (DMSO-d6) δ 9.06 (s, 1H), 8.86 (s, 1H), 8.12 (s, 1H), 6.96~6.68 (m, 4H),
5.55 (s, 2H), 5.46 (s, 1H), 5.31 (s, 1H), 4.60 (s, 1H), 4.39 (s, 1H), 3.95~3.19 (m, 9H), 3.29
(s, 6H), 2.77~2.55 (m, 2H), 1.89~1.62 (m, 2H), 1.24 (m, 3H)
13C NMR(DMSO-d6)δ171.2,155.7,130.2,129.2,116.0,115.8,104.7,88.7,78.6,
72.3,65.3,64.2,62.5,59.2,56.4,49.9,38.7,34.6,27.1,21.0.
Compound 20, yield 80%.
lH-NMR(DMSO-d6)δ8.52(s,1H),8.10(s,1H),5.52(s,2H),5.47(s,1H),5.31(s,
1H), 4.62 (s, 1H), 4.37 (s, 1H), 3.90~3.39 (m, 9H), 3.26 (s, 6H), 2.77~2.57 (m, 2H), 1.89~
1.62(m,3H),1.54(s,3H),1.24(m,3H),0.94(m,6H).
13C NMR(DMSO-d6)δ174.0,116.2,104.2,88.1,78.1,72.3,72.0,65.1,64.9,62.1,
59.7,50.2,37.3,34.1,27.4,23.7,21.7,16.0.
Embodiment 5
Tulase H37Rv activity investigate and antibiotic after benefit test, test method referring to ACS Infect.Dis.,
Just Accepted Manuscript·DOI:10.1021/acsinfecdis.6b00158.Experimental result see the table below.
Table 1 is to tulase H37Benefit after the investigation of Rv activity and antibiotic
Spectinomycin derivative shows through results of pharmacodynamic test：With the resistive connection similar to spectinomycin amide derivatives
Core acts on, and the novel spectinomycin derivative that 20 amino acid introduce is improved the antibacterial activity of tubercle bacillus, and resist
Tuberculosis action time is extended.The novel spectinomycin derivative of the present invention has lower than spectinomycin amide derivatives
Toxicity and more significant drug action.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
With within principle, any modification, equivalent replacement, improvement and so on should all be included in the protection scope of the present invention god.
Claims (10)
1. a kind of spectinomycin derivative, which is characterized in that any one natural amino acid (AA-OH) is introduced into spectinomycin
On the A cyclocarbonyls of molecule, general structure is Formulas I,
2. the preparation method of spectinomycin derivative as described in claim 1, which is characterized in that include the following steps：
(1) amido protecting of spectinomycin；
(2) carbonyl reduction of step (1) amido protecting product；
(3) amidation：In organic solvent, the natural amino acid of step (2) the carbonyl reduction product and amido protecting is added in,
The molar ratio of the natural amino acid of step (2) product and amido protecting is 1:1~2, under the catalysis of condensing agent, reaction 1
~48 hours, obtain amidated products；
(4) amidated products are deprotected to obtain spectinomycin derivative products.
3. the preparation method of spectinomycin derivative as claimed in claim 2, which is characterized in that
The step (1), under the conditions of 10~20 DEG C, spectinomycin hydrochloride is dissolved in the water, and reaction system pH is 2~4,
Add in alkali, will CbzCl add in organic solution in stir evenly, then add in reaction system, under the conditions of 25~50 DEG C react 1~
The molar ratio of 48h, the spectinomycin hydrochloride compound and CbzCl are 1:1~3, pass through acid for adjusting pH to 6.5~7.5, warp
Processing step obtains amido protecting product；
The step (2) in organic solvent, adds in amido protecting product and ammonium nitrate described in step (1), and the amino is protected
The molar ratio for protecting product and ammonium nitrate is 1:10~15, under acid catalysis, reaction is stirred at room temperature to clarifying, borane reagent is added in batches
Enter in reaction system, the molar ratio of the amido protecting product and borane reagent is 1:At 0.5~1.5,20~40 DEG C, it is stirred to react
1~2h obtains carbonyl reduction product through processing step；
The step (4), in acidic aqueous, adds in step (3) described amidated products, is hydrolyzed at 10~50 DEG C anti-
1~48h is answered, is obtained through processing step, obtains spectinomycin derivative.
4. method prepared by spectinomycin derivative as claimed in claim 2, which is characterized in that the condensing agent is o- (7-
Nitrogen benzotriazole)-N, N, N, N- tetramethylurea hexafluorophosphoric acid esters (HATU), benzotriazole -1- tetramethyl hexafluorophosphoric acid esters
(HBTU), any one in N-N '-diisopropylcarbodiimide (DIC).
5. method prepared by spectinomycin derivative as claimed in claim 3, which is characterized in that the alkali is sodium bicarbonate,
In saleratus, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, pyridine, diethylamine, triethylamine or n,N-Dimethylaniline
Any one.
6. method prepared by spectinomycin derivative as claimed in claim 3, which is characterized in that the acid is organic acid or nothing
Machine acid, the organic acid is any one in formic acid, acetic acid, oxalic acid, tartaric acid, lactic acid, citric acid or benzoic acid, described inorganic
Acid is any one in hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid.
7. method prepared by spectinomycin derivative as claimed in claim 3, which is characterized in that the concentration range 1 of the acid
~6mol/L.
8. method prepared by spectinomycin derivative as claimed in claim 3, which is characterized in that the borane reagent is hydroboration
Sodium, lithium borohydride, zinc borohydride, 9- boron-bicyclic [3.3.1] nonane dimer, borane-pyridine, borane-methyl pyridine, borine-
Any one or more in methyl sulfide or borine-tetrahydrofuran.
9. method prepared by spectinomycin derivative as claimed in claim 3, which is characterized in that the processing step is attached most importance to knot
Crystal method is detached or is used column chromatography method.
10. application of the spectinomycin derivative as claimed in claim 1 or 2 in antituberculotic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810139685.6A CN108148072A (en) | 2018-02-11 | 2018-02-11 | A kind of spectinomycin derivative and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810139685.6A CN108148072A (en) | 2018-02-11 | 2018-02-11 | A kind of spectinomycin derivative and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108148072A true CN108148072A (en) | 2018-06-12 |
Family
ID=62457412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810139685.6A Pending CN108148072A (en) | 2018-02-11 | 2018-02-11 | A kind of spectinomycin derivative and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108148072A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964026A (en) * | 2019-11-22 | 2020-04-07 | 中国医药集团总公司四川抗菌素工业研究所 | Preparation method of N, N-benzhydryloxyformyl spectinomycin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2851953A1 (en) * | 1978-12-01 | 1980-06-19 | Thomae Gmbh Dr K | 4-N-Substd. spectinomycyl-amine derivs. - useful as broad-spectrum antibacterial agents |
| CN102548552A (en) * | 2009-07-24 | 2012-07-04 | 田纳西大学研究基金会 | Spectinamides as anti-tuberculosis agents |
-
2018
- 2018-02-11 CN CN201810139685.6A patent/CN108148072A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2851953A1 (en) * | 1978-12-01 | 1980-06-19 | Thomae Gmbh Dr K | 4-N-Substd. spectinomycyl-amine derivs. - useful as broad-spectrum antibacterial agents |
| CN102548552A (en) * | 2009-07-24 | 2012-07-04 | 田纳西大学研究基金会 | Spectinamides as anti-tuberculosis agents |
Non-Patent Citations (1)
| Title |
|---|
| JIUYU LIU等: "Structure−Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions", 《ACS INFECT.DIS.》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964026A (en) * | 2019-11-22 | 2020-04-07 | 中国医药集团总公司四川抗菌素工业研究所 | Preparation method of N, N-benzhydryloxyformyl spectinomycin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002329634B2 (en) | Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain | |
| LV12574B (en) | Aza cyclohexapeptide compounds | |
| US9828413B2 (en) | Vancomycin derivative, and preparation method and application thereof | |
| CN103492409B (en) | Prepare the method for anti-mycotic agent | |
| AU2014310619A1 (en) | Peptide-oligourea chimeric compounds and methods of their use | |
| CN107226782A (en) | It is a kind of that there is pleuromutilin analog derivative of alkaline parahelium side chain and its preparation method and application | |
| CN108148072A (en) | A kind of spectinomycin derivative and its preparation method and application | |
| CN110551072A (en) | quinoxaline-N 1, N 4 -dioxide derivative with DNA topoisomerase activity inhibition function, preparation method and application | |
| CN101514200B (en) | Compound of aztreonam and a synthetic method thereof | |
| US8586552B2 (en) | 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics | |
| CN101029131A (en) | Branching poly-ethylene and its production | |
| CN108218886A (en) | A kind of novel spectinomycin derivative and its preparation method and application | |
| CN101735286A (en) | Amino acid modified glucosamine as well as preparation method and application thereof | |
| US20220047708A1 (en) | Glucose sensitive insulins and uses thereof | |
| CN105801438A (en) | Synthetic method of mirabegron intermediate | |
| WO2020057422A1 (en) | Vancomycin sulfonium derivative and preparation method therefor, pharmaceutical composition, and uses | |
| CN107089967A (en) | A kind of preparation method of R lipoic acids cholinester halide | |
| CN112961153B (en) | Preparation method of moxifloxacin impurity | |
| CN109280044B (en) | Raltitrexed impurity C and preparation and application thereof | |
| CN113975404B (en) | Florfenicol polypeptide derivative and application thereof | |
| CN110143957A (en) | The preparation method of Cefditoren pivoxil Cephalosporins ring-opening product | |
| KR102697956B1 (en) | Antimicrobial aminoglycoside derivatives | |
| CN101838345B (en) | Fluorine-18 marked galactosylated chitosan compound and preparation method thereof | |
| CN114163348A (en) | Synthesis method of aminoacyl-substituted L-phenylalanine | |
| AU599062B2 (en) | De-(acetylglucosaminyl)-di(dehydro)-deoxy teicoplanin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180612 |
|
| RJ01 | Rejection of invention patent application after publication |